Nicotine patch

A nicotine patch is a transdermal patch that releases nicotine into the body through the skin. It is used in nicotine replacement therapy (NRT), a process for smoking cessation. Endorsed and approved by the U.S. Food and Drug Administration (FDA), it is considered one of the safer NRTs available for the treatment of tobacco use disorder. Nicotine replacement products including gum and transdermal patches are on the World Health Organization's List of Essential Medicines. A meta-analysis found that fewer than 20% of people treated with nicotine replacement therapy remain abstinent from smoking at one year. The first study of the pharmacokinetics of a transdermal nicotine patch in humans was published in 1984 by Jed Rose, Murray Jarvik, and Daniel Rose, and was followed by publication by Rose et al. (1985) of results of a study of smokers showing that a transdermal nicotine patch reduced craving for cigarettes. Frank Etscorn filed a patent in the United States on January the 23rd 1985 and was issued the patent on July 1, 1986. The University of California filed a competing patent application nearly three years after Etscorn's filing on February 19, 1988, which was granted on May 1, 1990. Subsequently, the U.S. Patent Office declared an interference action and, after a thorough review of conception, reduction to practice and patent filing dates, issued on September 29, 1993, a priority decision in favor of the Rose et al. patent. Research has shown that NRT in combination with Cognitive Behavioral Therapy (CBT) can improve the rates of smoking cessation in pregnant women. CBT counseling includes motivational interviewing, Transtheoretical Model of Behavior Change, and Social Cognitive Theory. Nicotine patches are under study to help relieve the symptoms of postoperative pain and to treat early dementia. Studies are being conducted about the use of transdermal nicotine patches to treat anxiety, depression, and inattentiveness in subjects with ADHD and to treat late-life depression.